Biotech strategy notes
This page covers recurring decision problems biotech leadership teams face when moving from scientific plausibility to fundable, executable strategy.
Core decision problems
- Which target-indication pairing has the strongest evidence-adjusted upside?
- Where is differentiation realistic versus crowded mechanisms?
- What is the shortest path to an investor-ready narrative without overclaiming?
Practical approach
- Anchor choices in reproducible evidence (target, disease, drug, and mechanism context).
- Separate biological conviction from commercial feasibility.
- Use explicit trade-offs: indication depth vs speed, novelty vs competition.